Spruce Street Capital LP purchased a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,421,532 shares of the company’s stock, valued at approximately $1,414,000. Century Therapeutics accounts for approximately 0.5% of Spruce Street Capital LP’s holdings, making the stock its 26th biggest holding. Spruce Street Capital LP owned about 1.63% of Century Therapeutics at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in IPSC. Prudential Financial Inc. purchased a new stake in shares of Century Therapeutics during the 2nd quarter valued at approximately $25,000. Qube Research & Technologies Ltd purchased a new stake in shares of Century Therapeutics during the 2nd quarter valued at approximately $38,000. Raymond James Financial Inc. purchased a new stake in shares of Century Therapeutics during the 2nd quarter valued at approximately $51,000. AQR Capital Management LLC raised its position in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares during the period. Hedge funds and other institutional investors own 50.20% of the company’s stock.
Century Therapeutics Trading Up 2.2%
Shares of IPSC stock opened at $2.30 on Tuesday. The firm has a fifty day moving average price of $2.28 and a 200 day moving average price of $1.90. The company has a market cap of $414.81 million, a P/E ratio of -2.02 and a beta of 1.56. Century Therapeutics, Inc. has a 12 month low of $0.44 and a 12 month high of $3.04.
Analysts Set New Price Targets
Several research firms have recently commented on IPSC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Monday, April 6th. Mizuho began coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price target on the stock. Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 24th. Leerink Partners set a $2.00 target price on shares of Century Therapeutics and gave the company a “market perform” rating in a report on Friday, March 13th. Finally, HC Wainwright lifted their target price on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Century Therapeutics currently has an average rating of “Hold” and a consensus target price of $4.75.
Check Out Our Latest Report on IPSC
Century Therapeutics Profile
Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.
The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.
Featured Articles
- Five stocks we like better than Century Therapeutics
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
